BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 35166989)

  • 1. Single nCounter assay for prediction of MYCN amplification and molecular classification of medulloblastomas: a multicentric study.
    Moreno DA; da Silva LS; Zanon MF; Bonatelli M; de Paula FE; de Medeiros Matsushita M; Teixeira GR; Santana IVV; Saggioro F; Neder L; Stavale JN; Malheiros SMF; Lima M; Hajj GNM; Garcia-Rivello H; Christiansen S; Nunes S; da Costa MJG; Soares MJ; Pinheiro J; Junior CA; Mançano BM; Reis RM
    J Neurooncol; 2022 Mar; 157(1):27-35. PubMed ID: 35166989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Approach to molecular subgrouping of medulloblastomas: Comparison of NanoString nCounter assay versus combination of immunohistochemistry and fluorescence in-situ hybridization in resource constrained centres.
    Kaur K; Jha P; Pathak P; Suri V; Sharma MC; Garg A; Suri A; Sarkar C
    J Neurooncol; 2019 Jul; 143(3):393-403. PubMed ID: 31104222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological and clinical heterogeneity of MYCN-amplified medulloblastoma.
    Korshunov A; Remke M; Kool M; Hielscher T; Northcott PA; Williamson D; Pfaff E; Witt H; Jones DT; Ryzhova M; Cho YJ; Wittmann A; Benner A; Weiss WA; von Deimling A; Scheurlen W; Kulozik AE; Clifford SC; Peter Collins V; Westermann F; Taylor MD; Lichter P; Pfister SM
    Acta Neuropathol; 2012 Apr; 123(4):515-27. PubMed ID: 22160402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exclusive Hyperfractionated Radiation Therapy and Reduced Boost Volume for Standard-Risk Medulloblastoma: Pooled Analysis of the 2 French Multicentric Studies MSFOP98 and MSFOP 2007 and Correlation With Molecular Subgroups.
    Carrie C; Kieffer V; Figarella-Branger D; Masliah-Planchon J; Bolle S; Bernier V; Laprie A; Supiot S; Leseur J; Habrand JL; Alapetite C; Kerr C; Dufour C; Claude L; Chapet S; Huchet A; Bondiau PY; Escande A; Truc G; Nguyen TD; Pasteuris C; Vigneron C; Muracciole X; Bourdeaut F; Appay R; Dubray B; Colin C; Ferlay C; Dussart S; Chabaud S; Padovani L; ;
    Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1204-1217. PubMed ID: 32768563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors.
    Northcott PA; Fernandez-L A; Hagan JP; Ellison DW; Grajkowska W; Gillespie Y; Grundy R; Van Meter T; Rutka JT; Croce CM; Kenney AM; Taylor MD
    Cancer Res; 2009 Apr; 69(8):3249-55. PubMed ID: 19351822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma.
    Ryan SL; Schwalbe EC; Cole M; Lu Y; Lusher ME; Megahed H; O'Toole K; Nicholson SL; Bognar L; Garami M; Hauser P; Korshunov A; Pfister SM; Williamson D; Taylor RE; Ellison DW; Bailey S; Clifford SC
    Acta Neuropathol; 2012 Apr; 123(4):501-13. PubMed ID: 22139329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spectrum of medulloblastoma subtypes and frequency of MYC amplification; Experience from a tertiary care center in Saudi Arabia.
    Alassiri AH; Alsufiani FM; Almutairi AA; Almohini IA; Aldosari MA; Essa MF
    Neurosciences (Riyadh); 2020 Jul; 25(3):218-221. PubMed ID: 32683405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic classification of pediatric medulloblastoma based on chromosome 17p loss, expression of MYCC and MYCN, and Wnt pathway activation.
    Park AK; Lee SJ; Phi JH; Wang KC; Kim DG; Cho BK; Haberler C; Fattet S; Dufour C; Puget S; Sainte-Rose C; Bourdeaut F; Grill J; Delattre O; Kim SK; Park WY
    Neuro Oncol; 2012 Feb; 14(2):203-14. PubMed ID: 22090452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics of medulloblastoma in children under age of three years.
    Ryzhova MV; Zheludkova OG; Kumirova ÉV; Shishkina LV; Panina TN; Gorelyshev SK; Khukhlaeva EA; Mazerkina NA; Matuev KB; Medvedeva OA; Tarasova EM; Kholodov BV; Kapitul'skaia OIu
    Zh Vopr Neirokhir Im N N Burdenko; 2013; 77(1):3-10; discussion 11. PubMed ID: 23659115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct.
    Northcott PA; Hielscher T; Dubuc A; Mack S; Shih D; Remke M; Al-Halabi H; Albrecht S; Jabado N; Eberhart CG; Grajkowska W; Weiss WA; Clifford SC; Bouffet E; Rutka JT; Korshunov A; Pfister S; Taylor MD
    Acta Neuropathol; 2011 Aug; 122(2):231-40. PubMed ID: 21681522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study.
    Schwalbe EC; Lindsey JC; Nakjang S; Crosier S; Smith AJ; Hicks D; Rafiee G; Hill RM; Iliasova A; Stone T; Pizer B; Michalski A; Joshi A; Wharton SB; Jacques TS; Bailey S; Williamson D; Clifford SC
    Lancet Oncol; 2017 Jul; 18(7):958-971. PubMed ID: 28545823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BarTeL, a Genetically Versatile, Bioluminescent and Granule Neuron Precursor-Targeted Mouse Model for Medulloblastoma.
    Shackleford GM; Shi XH; Swanson KS; Mahdi MY; Gonzalez-Gomez I; Asgharzadeh S; D'Apuzzo M; Erdreich-Epstein A; Moats RA
    PLoS One; 2016; 11(6):e0156907. PubMed ID: 27310018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort.
    Pietsch T; Schmidt R; Remke M; Korshunov A; Hovestadt V; Jones DT; Felsberg J; Kaulich K; Goschzik T; Kool M; Northcott PA; von Hoff K; von Bueren AO; Friedrich C; Mynarek M; Skladny H; Fleischhack G; Taylor MD; Cremer F; Lichter P; Faldum A; Reifenberger G; Rutkowski S; Pfister SM
    Acta Neuropathol; 2014 Jul; 128(1):137-49. PubMed ID: 24791927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk stratification of childhood medulloblastoma in the molecular era: the current consensus.
    Ramaswamy V; Remke M; Bouffet E; Bailey S; Clifford SC; Doz F; Kool M; Dufour C; Vassal G; Milde T; Witt O; von Hoff K; Pietsch T; Northcott PA; Gajjar A; Robinson GW; Padovani L; André N; Massimino M; Pizer B; Packer R; Rutkowski S; Pfister SM; Taylor MD; Pomeroy SL
    Acta Neuropathol; 2016 Jun; 131(6):821-31. PubMed ID: 27040285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children's Oncology Group.
    Aldosari N; Bigner SH; Burger PC; Becker L; Kepner JL; Friedman HS; McLendon RE
    Arch Pathol Lab Med; 2002 May; 126(5):540-4. PubMed ID: 11958658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolated Bone Recurrence of Medulloblastoma With MYCN Amplification and TP53 Loss: A Case Report.
    Takahashi Y; Kudo K; Ogawa K; Sato T; Kamio T; Sasaki S; Kobayashi A; Ito T; Yamamoto T; Asano K; Ohkuma H; Kurose A; Ito E; Terui K
    J Pediatr Hematol Oncol; 2022 Mar; 44(2):e593-e596. PubMed ID: 34133388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrating Molecular Subclassification of Medulloblastomas into Routine Clinical Practice: A Simplified Approach.
    Kaur K; Kakkar A; Kumar A; Mallick S; Julka PK; Gupta D; Suri A; Suri V; Sharma MC; Sarkar C
    Brain Pathol; 2016 May; 26(3):334-43. PubMed ID: 26222673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Digital expression profile of immune checkpoint genes in medulloblastomas identifies CD24 and CD276 as putative immunotherapy targets.
    Marques RF; Moreno DA; da Silva L; Leal LF; de Paula FE; Santana I; Teixeira G; Saggioro F; Neder L; Junior CA; Mançano B; Reis RM
    Front Immunol; 2023; 14():1062856. PubMed ID: 36825029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci.
    Pfister S; Remke M; Benner A; Mendrzyk F; Toedt G; Felsberg J; Wittmann A; Devens F; Gerber NU; Joos S; Kulozik A; Reifenberger G; Rutkowski S; Wiestler OD; Radlwimmer B; Scheurlen W; Lichter P; Korshunov A
    J Clin Oncol; 2009 Apr; 27(10):1627-36. PubMed ID: 19255330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups.
    Ellison DW; Dalton J; Kocak M; Nicholson SL; Fraga C; Neale G; Kenney AM; Brat DJ; Perry A; Yong WH; Taylor RE; Bailey S; Clifford SC; Gilbertson RJ
    Acta Neuropathol; 2011 Mar; 121(3):381-96. PubMed ID: 21267586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.